Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Endocrine Testing Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The market for endocrine testing has experienced robust expansion lately, projecting a rise from $2.79 billion in 2025 to $3.05 billion in 2026, fueled by a compound annual growth rate (CAGR) of 9.4%. This upward trajectory in the historical period is largely due to increasing rates of diabetes, a greater number of thyroid disorder cases, the proliferation of clinical laboratories, heightened public awareness regarding hormone testing, and the growing demand for diagnostics related to chronic diseases.
The market for endocrine testing is poised for substantial expansion over the coming years, with projections indicating a valuation of $4.15 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.9%. This projected growth during the forecast period is fueled by several key factors, including a heightened emphasis on preventive healthcare, the increasing implementation of personalized treatment strategies, advancements in the automation of hormone testing procedures, the broader establishment of diagnostic centers, and the proliferation of programs dedicated to screening for endocrine diseases. Furthermore, significant trends anticipated within this timeframe encompass the rising incidence of hormonal disorders, a greater uptake of extensive hormone panel testing, the expansion of proactive endocrine screening initiatives, an escalating demand for precise diagnostic outcomes, and the seamless integration of sophisticated diagnostic technologies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15562&type=smp
Endocrine Testing Market Growth Drivers: What Factors Are Accelerating Expansion?
The increasing incidence of diabetes is anticipated to be a key catalyst for the expansion of the endocrine testing market. Diabetes, characterized by elevated blood sugar (glucose) levels, is becoming more common due to factors like poor dietary habits, lack of physical activity, genetic factors, and an aging demographic. Endocrine tests, such as hemoglobin A1c, fasting plasma glucose, and C-peptide assays, are crucial for identifying diabetes, tracking blood sugar control, and evaluating the body’s insulin function. Notably, the UK’s National Health Service reported a substantial increase in diabetes cases among those under 40, jumping from 173,166 in 2022 to 216,440 in 2023, underscoring a significant and worrying surge in younger individuals affected by the condition. This pronounced rise in the occurrences of diabetes, particularly among the younger population, directly fuels the demand within the endocrine testing sector.
Endocrine Testing Market Segment Analysis Highlighting Growth Areas
The endocrine testing market covered in this report is segmented –
1) By Test Type: Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Other Types
2) By Technology: Tandem Mass Spectrometry, Immunoassay, Monoclonal And Polyclonal Antibody Technologies, Sensor Technology, Clinical Chemistry, Other Technologies
3) By End-User: Hospitals, Clinical Laboratories, Diagnostic Centers, Other End-Users
Subsegments:
1) By Estradiol (E2) Test: Serum Estradiol Test, Urinary Estradiol Test
2) By Follicle Stimulating Hormone (FSH) Test: FSH Serum Test, FSH Urine Test
3) By Human Chorionic Gonadotropin (hCG) Hormone Test: Quantitative hCG Test, Qualitative hCG Test
4) By Luteinizing Hormone (LH) Test: LH Serum Test, LH Urine Test
5) By Dehydroepiandrosterone Sulfate (DHEAS) Test: Serum DHEAS Test, Saliva DHEAS Test
6) By Progesterone Test: Serum Progesterone Test, Urinary Progesterone Test
7) By Testosterone Test: Free Testosterone Test, Total Testosterone Test
8) By Thyroid Stimulating Hormone (TSH) Test: TSH Serum Test, TSH Saliva Test
9) By Prolactin Test: Serum Prolactin Test, Plasma Prolactin Test
10) By Other Types: Cortisol Test, Insulin Test, Growth Hormone (GH) Test, Aldosterone Test
Endocrine Testing Market Trends: What Is Shaping Future Industry Growth?
To improve how easily and effectively endocrine conditions are identified, leading players in the endocrine testing sector are formulating point-of-care testing options. These near-patient tests provide swift results, which are instrumental in the speedy diagnosis and handling of heart failure in individuals exhibiting symptoms like breathlessness and weariness. As an illustration, in April 2024, the Swiss pharmaceutical firm Roche Holding AG introduced its point-of-care NT-proBNP test within India, crafted particularly for the screening of diabetic individuals susceptible to cardiovascular ailments, including heart failure. This innovation streamlines the identification and intervention process, empowering healthcare providers to pinpoint type 2 diabetes patients at significant risk and commence prompt therapeutic conversations, thereby fostering better patient results and overall health.
Endocrine Testing Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the endocrine testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Roche Holding, Siemens Healthineers, Quest Diagnostics, Agilent Technologies Inc., PerkinElmer Inc., BioMérieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., SD Biosensor Inc., Qiagen N.V., Ortho Clinical Diagnostics, Kronus Inc., Randox Laboratories Ltd., Fujirebio Diagnostics Inc., Inova Diagnostics Inc., Sekisui Diagnostics LLC, Mercodia AB, ZEUS Scientific Inc., IBL International, Monobind Inc., Agilus Diagnostics, Tosoh Bioscience Inc., DiaSorin S.p.A.
Access The Complete Endocrine Testing Market Report:
https://www.thebusinessresearchcompany.com/report/endocrine-testing-global-market-report
Endocrine Testing Market Largest Region: Which Geography Holds The Highest Market Share?
North Americawas the largest region in the endocrine testing market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the endocrine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
